Mylan’s Fulphila has secured an 8% share

Mylan has declared itself “very happy” with the progress of its Fulphila (pegfilgrastim-jmdb) rival to Neulasta, after revealing that the biosimilar – co-developed with India’s Biocon – has captured just over 8% of the pegfilgrastim pre-filled syringe market in the US.

Mylan has declared itself “very happy” with the progress of its Fulphila (pegfilgrastim-jmdb) rival to Neulasta, after revealing that the biosimilar – co-developed with India’s Biocon – has captured just over 8% of the pegfilgrastim pre-filled syringe market in the US.

Noting that the pre-filled syringe market represented “almost 50% of the entire Neulasta marketplace” in the US, the company said...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business